Sara Galimberti

Sara Galimberti graduated in Medicine and Surgery in 1992 at the University of Pisa and Scuola Superiore di Studi Universitari e Perfezionamento “Sant’Anna”. She carried out a 3-years post-graduate course in experimental medicine and in 1996 she obtained a Ph.D. She is currently Associate Professor at the Clinical and Experimental Medicine Department, Hematology Section of the University of Pisa, chief of the School in Specialization in Hematology, Scientific Responsible for the Molecular Section of the Hematology Division and Responsible for chronic Myeloproliferative and lymphoproliferative diseases at Hematology of Pisa. From 1994 she followed several national trials about acute leukemia and chronic lymphocytic leukemia (CLL) coordinated by the GIMEMA Italian Group. In the 1999-2001 she worked for the MURST project, coordinated by Prof. S. Tura about Minimal residual disease in multiple myeloma patients candidate to autologous transplantation. Her laboratory is the referee for diagnostic molecular tests for all hospitals in the West coast of Tuscany and is one of the 4 laboratories of the FILMRD NETWORK, referee centers for the assessment of the minimal residual disease in the clinical trials coordinated by the Italian Foundation for Lymphoma Studies (FIL). Dr. Galimberti was involved in many clinical trials, especially in CML, according to GMP rules. In the CML setting, Dr. Galimberti is responsible of the hematological aspects of the TIKLET trial (pharmacokinetics,pharmacodynamics of TKIs). Principal research areas: multidrug resistance, minimal residual disease, histone deacetylase inhibitors,arsenic trioxide, bortezomib, gamma delta lymphocytes, methylation, aGVHD, CML.